Jamie B. Spangler

Affiliations: 
2011-2017 Stanford University, Palo Alto, CA 
 2017- Chemical & Biomolecular Engineering Johns Hopkins University, Baltimore, MD 
Google:
"Jamie Spangler"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Yang H, Karl MN, Wang W, et al. (2022) Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis. Molecular Therapy : the Journal of the American Society of Gene Therapy
Bernstein ZJ, Spangler JB. (2021) Insights into the anticancer mechanisms of interleukin-15 from engineered cytokine therapies. The Journal of Clinical Investigation. 131
Glassman CR, Mathiharan YK, Jude KM, et al. (2021) Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. Cell. 184: 983-999.e24
VanDyke D, Wang W, Spangler JB. (2020) Innovative synthetic signaling technologies for immunotherapy Current Opinion in Biomedical Engineering. 16: 1-8
Yang H, Kureshi R, Spangler JB. (2019) Structural Basis for Signaling Through Shared Common γ Chain Cytokines. Advances in Experimental Medicine and Biology. 1172: 1-19
Spangler JB, Moraga I, Jude KM, et al. (2019) A strategy for the selection of monovalent antibodies that span protein dimer interfaces. The Journal of Biological Chemistry
Leonard EK, Leff MI, Spangler JB. (2019) Weaponizing T-cell receptors through molecular engineering. The Journal of Biological Chemistry. 294: 5805-5806
Krohl PJ, Ludwig SD, Spangler JB. (2019) Emerging technologies in protein interface engineering for biomedical applications. Current Opinion in Biotechnology. 60: 82-88
Silva DA, Yu S, Ulge UY, et al. (2019) De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 565: 186-191
Spangler JB, Trotta E, Tomala J, et al. (2018) Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy. Journal of Immunology (Baltimore, Md. : 1950)
See more...